5-hydroxymethylcytosine has been researched along with Kahler Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bhatti, P; Chiu, BC; Derman, BA; He, C; Jakubowiak, A; Karpus, J; Langerman, SS; Luo, L; Sukhanova, M; Zhang, S; Zhang, W; Zhang, Z | 1 |
| Alberge, JB; Attal, M; Avet-Loiseau, H; Campion, L; Carell, T; Denié, S; Guérin-Charbonnel, C; Magrangeas, F; Minvielle, S; Moreau, P; Sérandour, AA; Wagner, M | 1 |
| Kanno, H; Nakazawa, K; Ohya, M | 1 |
3 other study(ies) available for 5-hydroxymethylcytosine and Kahler Disease
| Article | Year |
|---|---|
Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma.
Topics: 5-Methylcytosine; Cell-Free Nucleic Acids; Humans; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma | 2022 |
DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma.
Topics: 5-Methylcytosine; Chromatin; Cyclin D1; Cyclin D2; DNA Methylation; Epigenesis, Genetic; Epigenomics; Female; Gene Expression Regulation, Neoplastic; Genome; Histone-Lysine N-Methyltransferase; Humans; Male; Middle Aged; Multiple Myeloma; Phenotype; Proto-Oncogene Proteins c-myc; Regulatory Sequences, Nucleic Acid; Repressor Proteins; Severity of Illness Index | 2020 |
Lower number of 5-hydroxymethylcytosine-expressing cells in plasma cell myeloma than in reactive plasma cell hyperplasia: a useful immunohistochemical approach for identification of neoplastic plasma cells.
Topics: 5-Methylcytosine; Aged; Aged, 80 and over; Diagnosis, Differential; Female; Humans; Hyperplasia; Immunohistochemistry; Male; Middle Aged; Multiple Myeloma; Plasma Cells | 2019 |